Healthcare Analysts discuss emerging therapies in chronic myeloid leukemia (CML), (relevant companies NVS, ENLV, TERN, TAK, BMY, PFE) on an ...
Combining proteasome inhibitors with autophagy inhibitors disrupts acute myeloid leukemia (AML) cells' proteostasis, ...
Terns Pharmaceuticals halts its TERN-601 obesity program due to insufficient efficacy and safety concerns. Click here to read ...
The US FDA has accepted the new drug application (NDA) for XS003, a formulation referencing the tyrosine kinase inhibitor (TKI) nilotinib (Tasigna), for treatment of chronic myeloid leukemia (CML). 1 ...
The FALCON Phase 2 trial is a U.S.-based, multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of TERN-601, a novel oral GLP-1R agonist, with once-daily ...
After Novartis (NVS) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive ...
If approved, Scemblix will be indicated for adults with chronic myeloid leukemia (CML), both newly diagnosed and previously treated, expanding access to four times as many patients in EuropeScemblix ...
When oral medicines for Chronic Myeloid Leukemia (CML) first became available, they dramatically changed what it meant to ...
7d
Cycle Pharmaceuticals Launches Its First Oncology Product, PHYRAGO™ (dasatinib) Tablets, in the US
Cycle Pharmaceuticals announces the launch of PHYRAGO, its first oncology product in the US. PHYRAGO is launched in ...
2025 BofA China Trailblazers Biotech Conference: One-on-one investor meetings on October 20-21 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback